Is Cardura (doxazosin) appropriate for facilitating passage of distal ureteral stones ≤10 mm, and what is the recommended dosing and precautions?

Cardura (Doxazosin) for Distal Ureteral Stones ≤10 mm

Yes, Cardura (doxazosin) is highly appropriate and strongly recommended for facilitating passage of distal ureteral stones ≤10 mm as medical expulsive therapy (MET). The 2026 AUA guidelines provide a Strong Recommendation (Grade A evidence) that alpha-adrenergic blockers, including doxazosin specifically, should be offered to all adult and pediatric patients with distal ureteral stones ≤10 mm 1.

Evidence Supporting Doxazosin

The most recent 2026 AUA guideline meta-analysis of 49 studies comprising over 8,000 patients demonstrated that alpha-blockers (including doxazosin) significantly:

• Increase stone passage rates compared to control groups
• Reduce pain episodes and analgesic requirements
• Decrease unplanned healthcare encounters (emergency department visits)
• Lower the need for surgical intervention 1

A 2026 network meta-analysis ranked doxazosin as the second most effective alpha-blocker after terazosin, and superior to tamsulosin, alfuzosin, and naftopidil 2. This is particularly noteworthy given that tamsulosin is the most commonly prescribed agent.

Recommended Dosing

Start with doxazosin 4 mg once daily for approximately 30 days 1. The evidence supports:

• 4 mg daily is the optimal dose for MET purposes 3, 4
• A 2017 RCT directly comparing 4 mg versus 8 mg doxazosin found no significant difference in efficacy between doses (72% vs 68.1% stone expulsion rates, p=0.207) 3
• Both doses showed equal safety profiles and pain control 3

Important distinction: The FDA-approved dosing for BPH (4-8 mg) differs from MET use. For stone passage, 4 mg is sufficient and avoids unnecessary dose escalation 5.

Clinical Outcomes with Doxazosin

Multiple high-quality studies demonstrate:

• Stone expulsion rate: 68-85% with doxazosin versus 25-60% with placebo 6, 3, 4, 7
• Expulsion time reduction: Approximately 4-5 days faster than placebo (mean difference -4.03 days) 6
• Particularly effective for 5-10 mm stones: Higher efficacy than for smaller stones 7
• Superior to tamsulosin in expulsion time: 0.61 days shorter (p=0.001) 6

Critical Precautions

Postural Hypotension

Monitor for orthostatic hypotension, especially within the first few hours after initial dosing 5. While the FDA label emphasizes this risk for BPH treatment, it applies equally to MET use. Warn patients to:

• Rise slowly from sitting/lying positions
• Avoid driving or hazardous activities if experiencing dizziness
• Report syncope or severe dizziness immediately

Drug Interactions

Exercise caution with concomitant PDE-5 inhibitors (sildenafil, tadalafil, etc.) due to additive blood pressure lowering effects 5. If both medications are necessary, initiate the PDE-5 inhibitor at the lowest dose.

Cataract Surgery

Inform ophthalmologists if patient is scheduled for cataract surgery, as doxazosin can cause Intraoperative Floppy Iris Syndrome (IFIS) 5. However, do not discontinue therapy preoperatively as this does not prevent IFIS.

Contraindications

Do not use in patients with known hypersensitivity to quinazolines (doxazosin, prazosin, terazosin) 5.

Common Pitfalls to Avoid

1. Don't use the extended-release formulation (Cardura XL) for MET—this is FDA-approved only for BPH, not stone passage. Use immediate-release doxazosin 5.

2. Don't exceed 4 mg daily for MET—higher doses provide no additional benefit for stone passage 3.

3. Don't continue beyond 30 days without reassessment—if the stone hasn't passed by 4 weeks, consider ureteroscopy or other interventions 1.

4. Don't forget to address pain control—combine with NSAIDs (diclofenac, ibuprofen) as first-line analgesia 8, 4.

Location-Specific Efficacy

Strongest evidence exists for distal ureteral stones (Strong Recommendation, Grade A) 1. For middle and proximal ureteral stones ≤10 mm, the recommendation is weaker (Conditional Recommendation, Grade B), as meta-analysis showed no significant difference in spontaneous expulsion rates 1.

Adverse Effects

Doxazosin is generally well-tolerated with a favorable safety profile:

• Number Needed to Harm (NNH) = 38 2
• Most common side effects: dizziness, headache, fatigue (mild and self-limiting) 6, 4
• Lower rate of retrograde ejaculation compared to silodosin 2, 9
• No serious adverse events reported in major trials 6, 4, 7

Pediatric Considerations

Doxazosin is also effective in pediatric patients with distal ureteral stones 1, 10. A 2023 meta-analysis confirmed alpha-blockers increase stone expulsion rates (RR 1.42) and decrease expulsion time by 5.18 days in children, though with higher rates of minor adverse effects (headache, dizziness, nasal congestion) 10.

When to Abandon MET

Proceed to surgical intervention (ureteroscopy) if:

• No stone passage after 30 days of MET 1
• Persistent obstruction causing hydronephrosis
• Signs of infection/sepsis (requires urgent decompression) 8
• Intractable pain despite adequate analgesia
• Patient preference for definitive treatment

The bottom line: Doxazosin 4 mg once daily for 30 days is an evidence-based, cost-effective first-line therapy for distal ureteral stones ≤10 mm, with particular benefit for stones 5-10 mm in size. It reduces the need for surgical intervention while improving patient comfort and outcomes.